Ocular Therapeutix Revenue and Competitors
Estimated Revenue & Valuation
- Ocular Therapeutix's estimated annual revenue is currently $2M per year.
- Ocular Therapeutix received $37.5M in venture funding in February 2019.
- Ocular Therapeutix's estimated revenue per employee is $8,057
- Ocular Therapeutix's total funding is $138.4M.
- Ocular Therapeutix has 247 Employees.
- Ocular Therapeutix grew their employee count by 5% last year.
Ocular Therapeutix Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Ocular Therapeutix?
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix's lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
Ocular Therapeutix News
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected to Post Quarterly Sales of $15.03 Million. Posted by admin on Apr 19th, 2022.
Ocular Therapeutix to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
This article is an update to my earlier piece in which I explained why I was buying the dip on Ocular Therapeutix (NASDAQ:OCUL),...
BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, reported preliminary net product revenue for the quarter ended June 30, 2021, and in ...
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary net product revenue for the quarter ended June 30, 2021, and in-market uni ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Ocular Therapeutix Funding
|2017-01-25||$25.0M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2018-01-26||$37.3M||Undisclosed||Piper Jaffray & Co||Article|